Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$28.24
-0.5%		$25.14
$19.69
▼
$29.85
$4.89B0.811.73 million shs1.06 million shs
Celcuity, Inc. stock logo
CELC
Celcuity
$92.00
+6.2%		$93.88
$44.42
▼
$151.02
$4.22B0.21.10 million shs1.33 million shs
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
$25.70
-1.0%		$22.83
$11.65
▼
$27.31
$4.85B1.072.72 million shs1.68 million shs
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
$23.03
-1.1%		$18.55
$6.50
▼
$50.20
$1.38B1.73842,699 shs417,560 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
-0.49%-3.32%+8.95%+31.96%+12.27%
Celcuity, Inc. stock logo
CELC
Celcuity
+6.24%-0.85%+0.54%-33.18%+75.67%
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-1.00%-2.10%+7.13%+48.64%+109.97%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
-1.12%-2.70%+27.38%+57.42%-43.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$28.24
-0.5%		$25.14
$19.69
▼
$29.85
$4.89B0.811.73 million shs1.06 million shs
Celcuity, Inc. stock logo
CELC
Celcuity
$92.00
+6.2%		$93.88
$44.42
▼
$151.02
$4.22B0.21.10 million shs1.33 million shs
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
$25.70
-1.0%		$22.83
$11.65
▼
$27.31
$4.85B1.072.72 million shs1.68 million shs
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
$23.03
-1.1%		$18.55
$6.50
▼
$50.20
$1.38B1.73842,699 shs417,560 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
-0.49%-3.32%+8.95%+31.96%+12.27%
Celcuity, Inc. stock logo
CELC
Celcuity
+6.24%-0.85%+0.54%-33.18%+75.67%
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-1.00%-2.10%+7.13%+48.64%+109.97%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
-1.12%-2.70%+27.38%+57.42%-43.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
2.82
Moderate Buy$33.6919.31% Upside
Celcuity, Inc. stock logo
CELC
Celcuity
2.82
Moderate Buy$153.6467.00% Upside
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
2.87
Moderate Buy$34.4233.92% Upside
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
2.82
Moderate Buy$43.3888.34% Upside

Current Analyst Ratings Breakdown

Latest VOR, ACAD, DYN, and CELC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/14/2026
Celcuity, Inc. stock logo
CELC
Celcuity
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$155.00
8/14/2026
Celcuity, Inc. stock logo
CELC
Celcuity
Stifel Nicolaus logo
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$175.00 ➝ $150.00
8/14/2026
Celcuity, Inc. stock logo
CELC
Celcuity
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$157.00 ➝ $140.00
8/12/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C) ➝ Hold (C+)
8/12/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$38.00 ➝ $41.00
8/12/2026
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$18.00 ➝ $27.00
8/11/2026
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D-) ➝ Sell (D+)
8/10/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$27.00
8/10/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$35.00 ➝ $39.00
8/6/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/5/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$36.00 ➝ $37.00
(Data available from 8/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$1.14B4.27$0.85 per share33.20$7.58 per share3.73
Celcuity, Inc. stock logo
CELC
Celcuity
N/AN/AN/AN/A$2.17 per shareN/A
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
N/AN/AN/AN/A$3.76 per shareN/A
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$391M$2.2212.7229.7323.1933.42%9.03%6.79%N/A
Celcuity, Inc. stock logo
CELC
Celcuity
-$177.04M-$4.30N/A4,600.00N/AN/A-244.61%-50.22%N/A
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-$446.21M-$3.33N/AN/AN/AN/A-64.30%-50.33%N/A
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/AN/AN/AN/AN/AN/AN/A

Latest VOR, ACAD, DYN, and CELC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Celcuity, Inc. stock logo
CELC
Celcuity
-$1.16-$1.44-$0.28-$1.44$4.42 million$0.09 million
8/11/2026Q2 2026
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
-$0.69-$0.80-$0.11-$1.16N/AN/A
8/4/2026Q2 2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$0.0682$0.18+$0.1119$0.18$296.55 million$308.00 million
7/30/2026Q2 2026
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-$0.7488-$1.08-$0.3312-$1.08N/AN/A
5/14/2026Q1 2026
Celcuity, Inc. stock logo
CELC
Celcuity
-$1.07-$0.97+$0.10-$0.97$2.94 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
N/AN/AN/AN/AN/A
Celcuity, Inc. stock logo
CELC
Celcuity
N/AN/AN/AN/AN/A
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
N/AN/AN/AN/AN/A
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
N/A
3.39
3.30
Celcuity, Inc. stock logo
CELC
Celcuity
6.04
12.31
12.31
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
0.28
12.02
12.02
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
96.71%
Celcuity, Inc. stock logo
CELC
Celcuity
63.33%
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
96.68%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
97.29%

Insider Ownership

CompanyInsider Ownership
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
26.20%
Celcuity, Inc. stock logo
CELC
Celcuity
13.33%
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
9.46%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
0.27%
CompanyEmployeesShares OutstandingFree FloatOptionable
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
510172.31 million127.16 millionOptionable
Celcuity, Inc. stock logo
CELC
Celcuity
4048.77 million42.27 millionOptionable
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
100186.75 million169.08 millionOptionable
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
14059.16 million54.04 millionN/A

Recent News About These Companies

Wall Street Zen Upgrades Vor Biopharma (NASDAQ:VOR) to Hold
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/wall-street-zen-upgrades-vor-biopharma-nasdaqvor-to-hold-2026-08-15/
Q3 EPS Estimates for Vor Biopharma Reduced by HC Wainwright
August 14 at 8:11 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/q3-eps-estimates-for-vor-biopharma-reduced-by-hc-wainwright-2026-08-14/
Wedbush Increases Vor Biopharma (NASDAQ:VOR) Price Target to $27.00
August 14 at 2:24 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30959642
Vor Biopharma (NASDAQ:VOR) Stock Price Down 6.5% Following Weak Earnings
August 14 at 1:40 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30959302
Vor Biopharma FY2030 EPS Forecast Reduced by HC Wainwright
August 13 at 7:56 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/vor-biopharma-fy2030-eps-forecast-reduced-by-hc-wainwright-2026-08-13/
Wedbush Issues Positive Forecast for Vor Biopharma (NASDAQ:VOR) Stock Price
August 12 at 12:17 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/wedbush-issues-positive-forecast-for-vor-biopharma-nasdaqvor-stock-price-2026-08-12/
Vor Biopharma (NASDAQ:VOR) Trading Down 6.5% on Disappointing Earnings
August 12 at 10:39 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/vor-biopharma-nasdaqvor-trading-down-65-on-disappointing-earnings-2026-08-12/
Vor Biopharma Shares Drop After Q2 Results
August 11, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vor-biopharma-shares-drop-q2-140534024.html
Vor Biopharma (NASDAQ:VOR) Posts Earnings Results
August 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/vor-biopharma-nasdaqvor-posts-earnings-results-2026-08-11/
Vor Biopharma: Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 11, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69277816-vor-biopharma-vor-bio-reports-second-quarter-2026-financial-results-and-provides-corporate-update-399.htm
Renaissance Technologies LLC Makes New $2.30 Million Investment in Vor Biopharma Inc. $VOR
August 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-renaissance-technologies-llc-makes-new-230-million-investment-in-vor-biopharma-inc-vor-2026-08-11/
Vor Biopharma Inc. (NASDAQ:VOR) Given Average Rating of "Moderate Buy" by Analysts
August 9, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30949739
Vor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Rating of "Moderate Buy" from Analysts
August 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/vor-biopharma-inc-nasdaqvor-receives-consensus-rating-of-moderate-buy-from-analysts-2026-08-09/
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 3, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/03/3337912/0/en/vor-bio-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4.html
Vor Biopharma (NASDAQ:VOR) Stock Price Up 12% - What's Next?
July 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/vor-biopharma-nasdaqvor-stock-price-up-12-whats-next-2026-07-21/
Vor Biopharma (NASDAQ:VOR) Shares Down 5% - Here's Why
July 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/vor-biopharma-nasdaqvor-shares-down-5-heres-why-2026-07-20/
Vor Biopharma: Vor Bio Appoints David Zaccardelli to Board of Directors
July 8, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-07/68970529-vor-biopharma-vor-bio-appoints-david-zaccardelli-to-board-of-directors-399.htm
Vor Bio Appoints David Zaccardelli to Board of Directors
July 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/07/3323613/0/en/vor-bio-appoints-david-zaccardelli-to-board-of-directors.html
Vor Biopharma: A Financed Autoimmune Pivot With More Substance Than The Market Realizes
July 7, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4920412-vor-biopharma-a-financed-autoimmune-pivot-with-more-substance-than-the-market-realizes
Vor Biopharma Stock Short Interest Report | NASDAQ:VOR | Benzinga
July 3, 2026  |  benzinga.comhttps://www.benzinga.com/quote/VOR/short-interest
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/02/3321604/0/en/vor-bio-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
A cracked stock chart showing plunging lines above scattered circuit boards, symbolizing a tech-market breakdown.
3 Stocks Standing Out and 2 Losing Momentum as the Tech Rally Cracks
By Bridget Bennett | July 28, 2026
L3Harris logo on a panel with a satellite, drone, camera sensor, and network icons against a sunset sky.
L3Harris’ Record Backlog Makes Its Stock Sell-Off Look Overdone
By Thomas Hughes | July 31, 2026
Magnifying glass highlighting glowing candlestick chart bars against a dark background with an upward trending stock price line.
3 Overlooked Stocks Analysts Still Like as AI Trades Get Crowded
By Nathan Reiff | August 11, 2026
Stacks of aluminum ingots in a factory with a glowing upward price chart, symbolizing aluminum price surge in the industry.
Forging Profits: The Executive Order Sparking Aluminum
By Jeffrey Neal Johnson | July 23, 2026
Medical imaging scanner with exposed internal components being assembled in a manufacturing facility with computer workstations.
Inside Teledyne's Bold Bet on the Future of Medical Imaging
By Jeffrey Neal Johnson | August 14, 2026
ACADIA Pharmaceuticals stock logo

ACADIA Pharmaceuticals NASDAQ:ACAD

$28.24 -0.14 (-0.49%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$28.25 +0.01 (+0.04%)
As of 08/14/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Celcuity stock logo

Celcuity NASDAQ:CELC

$92.00 +5.40 (+6.24%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$92.88 +0.88 (+0.95%)
As of 08/14/2026 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Dyne Therapeutics stock logo

Dyne Therapeutics NASDAQ:DYN

$25.70 -0.26 (-1.00%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$25.54 -0.15 (-0.60%)
As of 08/14/2026 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Vor Biopharma stock logo

Vor Biopharma NASDAQ:VOR

$23.03 -0.26 (-1.12%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$23.02 -0.02 (-0.07%)
As of 08/14/2026 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas